reports
Press Release: Sanofi’s Teizeild recommended for EU approval by the CH...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human ...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approb...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10, qui démontre la capacité du Teizeild à retarder l’apparition du stade 3 du diabète de type 1 (DT1), par rapport au placebo, chez les adultes et les enfants atteints de DT1 de stad...
Sanofi: 1 director
A director at Sanofi bought 207 shares at 7,909p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
- Research Department
INFORME DIARIO 14 NOVIEMBRE + RDOS. ESPAÑA 3T’25. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, ACS, AENA, COLONIAL, MERLIN, REPSOL, SANTANDER, SECTOR ELÉCTRICO, TALGO. EUROPA: ALLIANZ, PROSUS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Toma de beneficios en mercado Las bolsas terminaron recogiendo beneficio...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares – October 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Octobre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 eurosSiège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...
- Alvaro del Pozo
- Jan Frederik Slijkerman
Telefonica: A new strategic plan/Before the CMD, grand plans were disc...
Last week, Telefonica held its capital markets day and presented its long-awaited new strategy and 3Q25 results. Ahead of the CMD, a radical change in direction, including M&A, was discussed in the media but any such grand plans were missing from its new Strategic Plan. Notably, Telefonica has cut its dividend, but this seems more of a way to deal with weaker free cash flow than a way to cut indebtedness. Also, its outlook for growth remains muted. We are disappointed by Telefonica's outlook for...
- Martin Marandon-Carlhian
- Sinan Doganli
- Usama Tariq
- Martin Marandon-Carlhian
- Sinan Doganli
- Usama Tariq
- Juan Ros-Padilla
- Luis Arredondo
- Luis Arredondo
ALMIRALL: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 260.2 M (+12.9% vs. +12.3% BS(e) and +13.1% consensus); EBITDA: € 58.9 M (+56.2% vs. +39.4% BS(e) and +41.1% consensus); EBIT: € 22.0 M (+746.2% vs. +405.8% BS(e) and +519.2% consensus); Net Profit: € 10.7 M (€ -5.5 M in 3Q’24 vs. € 5.91 M BS(e) and € 6.0 M consensus); 9M'25 vs. 9M'24 Results Sales: € 820.7 M (+12.8% vs. +12.6% BS(e) and +12.8% consensus); EBITDA: € 180.7 M (+27.1% vs. +22.6% BS(e) and +23.1% consensus); EBIT: € 67.4 M (+75.1% vs. +52.1% BS(e) an...
- Luis Arredondo
ALMIRALL: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 260,2 M euros (+12,9% vs +12,3% BS(e) y +13,1% consenso); EBITDA: 58,9 M euros (+56,2% vs +39,4% BS(e) y +41,1% consenso); EBIT: 22,0 M euros (+746,2% vs +405,8% BS(e) y +519,2% consenso); BDI: 10,7 M euros (-5,5 M euros en 9meses'24 vs 5,91 M euros BS(e) y 6,0 M euros consenso); Rdos. 9meses'25 vs 9meses'24: Ventas: 820,7 M euros (+12,8% vs +12,6% BS(e) y +12,8% consenso); EBITDA: 180,7 M euros (+27,1% vs +22,6% BS(e) y +23,1% consenso); EBIT: 67,4 M euros (+75,1% ...
- Research Department
IBERIAN DAILY 10 NOVEMBER + 3Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: ALMIRALL, GREENING, TALGO, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Tech stocks raise doubts on markets It was a week of drops on both sides of the Atlantic, with the IBEX falling below 16,000 against a backdrop of growing uncertainty surrounding company valuations, especially those linke...
- Research Department
INFORME DIARIO 10 NOVIEMBRE + RDOS. ESPAÑA Y EUROPA 3T’25. IDEAS DESTA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ALMIRALL, GREENING, TALGO, VISCOFAN. EUROPA: AIRBUS, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Las tecnológicas hacen dudar al mercado, pero el final del shutdown apunta a rebote Semana de caídas a ambos lados del Atlántico, co...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study m...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients a...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique... ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire de licence de mise sur le marché (sBLA) a été acceptée pour examen prioritaire par la FDA Les données de phase 3 qui v...
- Luis Arredondo
SACYR: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 1.175 Bn (2.8% vs. 3.1% BS(e) and 1.3% consensus); EBITDA: € 371 M (27.7% vs. 23.0% BS(e) and 20.1% consensus); EBIT: € 273 M (1.2% vs. 15.2% BS(e) and 20.2% consensus); Net Profit: € 31 M (41.5% vs. 35.1% BS(e) and 70.7% consensus). 9M'25 vs. 9M'24 Results Sales: € 3.412 Bn (4.6% vs. 4.7% BS(e) and 4.0% consensus); EBITDA: € 1.018 Bn (7.4% vs. 6.0% BS(e) and 5.1% consensus); EBIT: € 737 M (-15.2% vs. -10.9% BS(e) and -9.3% consensus); Net Profit: € 62 M (-16.2%...
- Luis Arredondo
SACYR: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 1.175 M euros (2,8% vs 3,1% BS(e) y 1,3% consenso); EBITDA: 371 M euros (27,7% vs 23,0% BS(e) y 20,1% consenso); EBIT: 273 M euros (1,2% vs 15,2% BS(e) y 20,2% consenso); BDI: 31 M euros (41,5% vs 35,1% BS(e) y 70,7% consenso). Rdos. 9M'25 vs 9M'24: Ventas: 3.412 M euros (4,6% vs 4,7% BS(e) y 4,0% consenso); EBITDA: 1.018 M euros (7,4% vs 6,0% BS(e) y 5,1% consenso); EBIT: 737 M euros (-15,2% vs -10,9% BS(e) y -9,3% consenso); BDI: 62 M euros (-16,2% vs -18,2% BS...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.